Automated insulin delivery with mylife™ CamAPS® FX and the mylife™ YpsoPump® insulin pump 2 February 2023 Advertorial Ypsomed Australia is pleased to introduce the mylife™ CamAPS® FX App – a new automated insulin dosing algorithm app that is housed on a smartphone for use with the mylife™ YpsoPump® insulin pump and is approved in Australia for use from ages 1 year and older*. How does mylife™ CamAPS® FX work? mylife™ CamAPS® FX is an adaptive, hybrid closed-loop solution that enables users of the mylife™ YpsoPump® insulin pump to better manage their glucose levels and to benefit from a uniquely adaptive and responsive algorithm that is housed on the user’s smartphone. The system: Automatically adjusts insulin delivery on the insulin pump based on Dexcom G6 sensor glucose readings Constantly learns and adapts to ever-changing insulin needs for each individual Adjusts to day and night, day-to-day and week-to-week variations in insulin requirements, and compensates for over- and under-dosing of the meal-time bolus Can be personalised with adjustable personable glucose targets Allows users to deliver a meal-time bolus directly from their smartphone discreetly and conveniently. There are three key components to the hybrid closed-loop system: mylife™ YpsoPump® insulin pump Compatible Android phone (visit www.dexcom.com/compatibility to ensure your phone and OS is compatible) Dexcom G6 sensor/transmitter. mylife™ YpsoPump®: small, smart design and discreet to wear Small and light – weighs only 83 grams1 Comfortable and discreet to wear day and night For more information about mylife™ CamAPS® FX and the mylife™ YpsoPump®, contact Ypsomed Australia – email [email protected], call 1800 447 042 (Free Call) or visit https://www.mylife-diabetescare.com *Additional age restrictions may apply depending on the chosen continuous glucose monitor and insulin pump. 1. Waldenmaier D. et al.: First User Experiences With a Novel Touchscreen-Based Insulin Pump System in Daily Life of Patients With Type 1 Diabetes Experienced in Insulin Pump Therapy. Journal of Diabetes Science and Technology. 2019;13(1):96-102. doi: 10.1177/1932296818785386 Disclaimer: Always read the label and use only as directed. Consult your healthcare professional to see if this product is right for you. CamAPS® is a registered trademark of CamDiab Ltd. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries. The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by Ypsomed is under license. Other trademarks and trade names are those of their respective owners.
Media releases 13 December 2024 Pollie Pedal Tasmania Returns in 2025: Celebrating 18 Years of Riding for Diabetes! Tasmania’s deputy premier, Guy Barnett, who lives with type 1 diabetes, is joining Pollie Pedal again this year to support... Continue Reading
News 12 December 2024 Expanded access to cheaper medicines for Australians living with type 2 diabetes Diabetes Australia thanks the Albanese Government for its decision to expand the Pharmaceutical Benefits Scheme (PBS) listings for Forxiga® and... Continue Reading
News 12 December 2024 Overweight and obesity overtakes smoking as leading health risk Being overweight and obese is now risking more Australians’ health than smoking according to new data, as a new government... Continue Reading